We are live on
!
Find out more
CS
Candriam SCA Portfolio holdings
AUM
$19.3B
1-Year Est. Return
39.18%
This Fund
S&P 500
This Quarter
Est. Return
+0.03%
1 Year Est. Return
+39.18%
3 Year Est. Return
+109.85%
5 Year Est. Return
+149.31%
10 Year Est. Return
+617.16%
AUM
$4B
AUM Growth
+$261M
(+7%)
Cap. Flow
+$281M
Cap. Flow
% of AUM
7.02%
Top 10 Holdings %
Top 10 Hldgs %
19.74%
Holding
679
New
127
Increased
246
Reduced
223
Closed
43
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amgen
AMGN
|
+$104M |
| 2 |
Apple
AAPL
|
+$60.7M |
| 3 |
Amazon
AMZN
|
+$47.5M |
| 4 |
American Express
AXP
|
+$28.7M |
| 5 |
Travelers Companies
TRV
|
+$27.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
First Solar
FSLR
|
+$28.1M |
| 2 |
Johnson & Johnson
JNJ
|
+$28.1M |
| 3 |
Clorox
CLX
|
+$26.2M |
| 4 |
TJX Companies
TJX
|
+$24.8M |
| 5 |
McKesson
MCK
|
+$23.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 24.39% |
| 2 | Financials | 11.87% |
| 3 | Technology | 10.68% |
| 4 | Communication Services | 10.67% |
| 5 | Consumer Discretionary | 9.43% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
401
Republic Services
RSG
$66.7B
| $1.1M | 0.03% |
23,141
-8,817
| -28% | -$400K |
|
|
INFI
402
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
| $1.09M | 0.03% |
209,000
-31,900
| -13% | -$195K |
|
403
Lazard
LAZ
$4.37B
| $1.09M | 0.03% |
+28,300
| New | +$1.02M |
|
|
ARIA
404
DELISTED
Ariad Pharmaceuticals Inc
ARIA
| $1.08M | 0.03% |
+170,000
| New | +$953K |
|
|
ESPR
405
DELISTED
Esperion Therapeutics
ESPR
| $1.08M | 0.03% |
64,000
-11,000
| -15% | -$177K |
|
|
CALA
406
DELISTED
Calithera Biosciences, Inc
CALA
| $1.07M | 0.03% |
9,510
-240
| -2% | -$27.2K |
|
407
Cummins
CMI
$91.7B
| $1.06M | 0.03% |
9,733
-49,326
| -84% | -$4.77M |
|
|
OMED
408
DELISTED
OncoMed Pharmaceuticals, Inc.
OMED
| $1.06M | 0.03% |
105,000
-20,700
| -16% | -$243K |
|
409
Expeditors International
EXPD
$22.9B
| $1.05M | 0.03% |
21,700
+1,807
| +9% | +$82.8K |
|
410
Atara Biotherapeutics
ATRA
$71.2M
| $1.05M | 0.03% |
+2,220
| New | +$999K |
|
|
BHI
411
DELISTED
Baker Hughes
BHI
| $1.05M | 0.03% |
+23,986
| New | +$1.04M |
|
412
Federal Realty Investment Trust
FRT
$10.9B
| $1.04M | 0.03% |
6,729
+4,214
| +168% | +$631K |
|
413
PPG Industries
PPG
$25.9B
| $1.02M | 0.03% |
9,243
+2,019
| +28% | +$199K |
|
|
TRIL
414
DELISTED
Trillium Therapeutics Inc.
TRIL
| $1.02M | 0.03% |
110,000
| – | – |
|
415
Norfolk Southern
NSC
$78.8B
| $1M | 0.03% |
12,095
-2,763
| -19% | -$209K |
|
416
Prudential Financial
PRU
$41.7B
| $998K | 0.03% |
13,888
+2,375
| +21% | +$166K |
|
|
DNB
417
DELISTED
Dun & Bradstreet
DNB
| $993K | 0.02% |
+9,690
| New | +$942K |
|
418
Tyson Foods
TSN
$20.2B
| $986K | 0.02% |
14,879
+7,999
| +116% | +$481K |
|
|
KTWO
419
DELISTED
K2M Group Holdings, Inc
KTWO
| $973K | 0.02% |
66,000
| – | – |
|
420
HF Sinclair
DINO
$15.9B
| $968K | 0.02% |
27,552
+14,624
| +113% | +$504K |
|
|
ZGNX
421
DELISTED
Zogenix, Inc.
ZGNX
| $965K | 0.02% |
105,000
-8,900
| -8% | -$89.2K |
|
422
PVH
PVH
$3.71B
| $954K | 0.02% |
9,680
-75,593
| -89% | -$5.95M |
|
423
Tapestry
TPR
$28.8B
| $951K | 0.02% |
23,841
| – | – |
|
424
Palo Alto Networks
PANW
$264B
| $948K | 0.02% |
35,064
+5,532
| +19% | +$136K |
|
425
Insmed
INSM
$23.2B
| $945K | 0.02% |
75,000
-133,800
| -64% | -$1.76M |
|
Similar funds
PCM
A
MGP
LF
SOMRS
BPA
MIM
Candriam SCA's Q1 2016 Portfolio in Review
As of Q1 2016, Candriam SCA held 679 positions worth $4B, up 7% from $3.74B the previous quarter. Its ten largest holdings account for 20% of the portfolio.
Candriam SCA deployed $281M of net new capital in Q1 2016, opening 127 new positions and adding to 246 existing holdings. Its largest new stake was Amgen: 700,333 shares worth $104M.
By sector, the portfolio is most concentrated in Healthcare at 24% of assets, down from 29% a quarter earlier, followed by Financials and Technology.
On the sell side, the largest reduction was First Solar, an estimated $28.1M trimmed.
- Candriam SCA's largest Q1 2016 buy was Amgen: 700,333 shares worth $104M.
- Candriam SCA added most to Mead Johnson Nutrition Company in Q1 2016, an estimated $22.2M increase.
- Candriam SCA's biggest Q1 2016 reduction was First Solar, cutting an estimated $28.1M.
- Candriam SCA fully exited Avangrid, Inc. in Q1 2016, selling an estimated $9.6M.
- Candriam SCA's ten largest holdings make up 20% of its $4B portfolio in Q1 2016.
- Candriam SCA opened 127 new positions and closed 43 in Q1 2016.
- Candriam SCA's portfolio value rose 7% quarter-over-quarter to $4B.
Based on Candriam SCA's 13F filing for Q1 2016, filed 27 Apr 2016.